Proof Of Concept Study Sets Stage For Human Trial
WISCONSINREPORT.COM (08/19/2015) – Combining an experimental DNA vaccine against prostate cancer, with a new type of immunotherapy drug, increased vaccine effectiveness in mice with prostate cancer, according to a new study by UW Carbone Cancer Center scientists. Dr. Douglas McNeel, the study’s lead author, said the “proof of concept study” sets the stage for a human trial of the combination therapy, which began this week when the first patient received the vaccine.
Read more